Inflammatory Skin Disease

  1. Quaglino P, Scarisbrick J, Roccuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P et al: Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol 2023, 37(4):680-688.
  2. Gupta AK, Wang T, Polla Ravi S, Bamimore MA, Piguet V, Tosti A: Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur Acad Dermatol Venereol 2023, 37(4):666-679.
  3. Eichenfield LF, Stein Gold L, Kircik LH, Werschler WP, Beer K, Draelos ZD, Tanghetti EA, Papp KA, Baldwin H, Lain E et al: Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study. Pediatr Dermatol 2023.
  4. Blauvelt A, Thaçi D, Papp KA, Ho V, Ghoreschi K, Kim BS, Miller M, Shen YK, You Y, Chan D et al: Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. The British journal of dermatology 2023.
  5. Croitoru DO, Piguet V: T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris. The Journal of investigative dermatology 2023.
  6. Abduelmula A, Gooderham MJ: Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion. J Cutan Med Surg 2023:12034754231163541.
  7. Papp KA, Melosky B, Sehdev S, Hotte SJ, Beecker JR, Kirchhof MG, Turchin I, Dutz JP, Gooderham MJ, Gniadecki R et al: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb) 2023.
  9. Whalen-Browne A, Williams HC, Chu DK: [Not Available]. Cmaj 2023, 195(10):E390-e391.
  10. Bowie AC, Tadrous M, Thiruchelvam D, Ivers NM, Mohan T, Tu K, Jaakkimainen L, Drucker AM: A comparison of family physician and dermatologist topical corticosteroid prescriptions: A population-based cross-sectional study. J Am Acad Dermatol 2023.
  11. Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S, Drogaris L, Geng Z, Zhan T, Messina I et al: Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial. Dermatol Ther (Heidelb) 2023:1-13.
  12. Draelos ZD, Adam DN, Hong CH, Lebwohl MG, Lynde CW, Nahm WK, Papp KA, Pariser DM, Stein Gold L, Stewart D et al: Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. The British journal of dermatology 2023.
  13. Bourkas AN, Pope E: Oral ivermectin treatment for an infant with crusted scabies. Cmaj 2023, 195(9):E334.
  14. García-Romero MT, Tollefson M, Pope E, Brandling-Bennett HA, Paller AS, Keimig E, Arkin L, Wanat KA, Humphrey SR, Werth VP et al: Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea. JAMA Dermatol 2023, 159(3):299-307.
  15. Maleki-Yazdi KA, Heen AF, Zhao IX, Guyatt GH, Suzumura EA, Makhdami N, Chen L, Winders T, Wheeler KE, Wang J et al: Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review. JAMA Dermatol 2023, 159(3):320-330.
  16. Alavi A, Anand N, Yamanaka-Takaichi M, Piguet V, Simmers J, Machado M, Todd A, Kirby J: Evaluating the hidradenitis odor and drainage scale (HODS): A new validated potential instrument to assess odor and drainage in hidradenitis suppurativa-A cross-sectional study. JAAD Int 2023, 10:75-76.
  17. Liy-Wong C, Tarango C, Pope E, Coates T, Bruckner AL, Feinstein JA, Schwieger-Briel A, Hubbard LD, Jane C, Torres-Pradilla M et al: Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. Orphanet J Rare Dis 2023, 18(1):38.
  18. Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M et al: Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology 2023, 188(3):330-340.
  19. Lebwohl MG, Hebert AA, Gooderham MJ: Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply. Jama 2023, 329(7):595.
  20. Seigel K, Croitoru D, Lena ER, Dienes S, Alsukait S, Piguet V: Utility of Rituximab in the Treatment of Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg 2023:12034754231154261.
  21. Wollenberg A, Kircik L, Simpson E, Brinker D, Katoh N, Rueda MJ, Issa M, Yang F, Feely M, Alexis A: Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials. Dermatitis 2023.
  22. Aaron M, Ramien ML, Powell J, McCuaig CC, Marcoux D, Piram M, Hatami A, Coulombe J: A retrospective single-centre case series of paediatric blistering severe cutaneous adverse reactions (SCARs): evaluation using new diagnostic classification confirms value of British Association of Dermatologists’ guidelines. Clin Exp Dermatol 2023.
  23. Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, Jones T, Saint-Cyr Proulx E, Bissonnette R et al: The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study. J Drugs Dermatol 2023, 22(2):139-147.
  24. Liu J, Cices A, Kaufman B, Sanabria-Gonzalez I, Alexis A: Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color. J Drugs Dermatol 2023, 22(2):165-173.
  25. Croitoru DO, Piguet V: Methylglyoxal Autoimmunity: A Hidden Link in HS and Associated Diseases? The Journal of investigative dermatology 2023, 143(2):183-185.
  26. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W et al: Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol 2023, 159(2):182-191.
  27. Gooderham M, Papp KA, Lynde C, Delorme I, Beecker J, Albrecht L, Dei-Cas I, Brassard D, Prajapati VH, Vieira A et al: Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry. Dermatol Ther (Heidelb) 2023, 13(2):535-553.
  28. Musters AH, Broderick C, Prieto-Merino D, Chiricozzi A, Damiani G, Peris K, Dhar S, De A, Freeman E, Arents BWM et al: The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol 2023, 37(2):365-381.
  29. Croitoru DO, Brooks SG, Nathanielsz N, Silverberg O, Nicolau I, Drucker AM, Silverberg M, Yeung J, Limacher JJ, Piguet V: Predictors of severity in paradoxical psoriasis from biologic therapies: A systematic review. J Am Acad Dermatol 2023, 88(2):471-473.
  30. Du AX, Ali Z, Ajgeiy KK, Dalager MG, Dam TN, Egeberg A, Nissen CVS, Skov L, Thomsen SF, Emam S et al: Machine learning model for predicting outcomes of biologic therapy in psoriasis. J Am Acad Dermatol 2023.
  31. Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, Lynde C, Prajapati VH, Wiseman M, Netchiporouk E: The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol 2023.
  32. Ong PY, Boguniewicz J, Chu DK: Skin Antiseptics for Atopic Dermatitis: Dissecting Facts From Fiction. J Allergy Clin Immunol Pract 2023.
  33. Zinter MS, Markovic D, Asaro LA, Nadkarni VM, McQuillen PS, Sinha P, Matthay MA, Jeschke MG, Agus MSD, Sapru A: Tight Glycemic Control, Inflammation, and the ICU: Evidence for Heterogeneous Treatment Effects in Two Randomized Controlled Trials. Am J Respir Crit Care Med 2023.
  34. Bourkas AN, Pope E, Mendoza-Londono R, Kamath BM, Lara-Corrales I: Early diagnosis of ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis syndrome: A case report. Pediatr Dermatol 2023.
  35. Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K et al: Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol 2023.
  36. Blauvelt A, Pariser DM, Tyring S, Bagel J, Alexis AF, Soung J, Armstrong AW, Muscianisi E, Kianifard F, Steadman J et al: Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci 2023.
  37. Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K et al: Executive Summary: American Academy of Dermatology Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol 2023.
  38. Williams JC, Alhusayen R, Guilbault S, Hills NK, Ingram JR, Kudlinski MV, Lowes MA, Marzano AV, Paul M, Villumsen B et al: Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Dermatology 2023, 239(2):283-286.
  39. Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB, Maari C, Papp KA: Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. J Cutan Med Surg 2023, 27(1_suppl):3s-24s.
  40. Papp KA, Gooderham M, Dei-Cas I, LopezTello A, Garcia-Rodriguez JC, Taveras CY, Rousselin AH, Lavieri A, Maiolino M, Quintero DGV et al: Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatol Ther (Heidelb) 2023, 13(1):269-283.
  41. Voisin A, Al-Ali A, Abduelmula A, Gooderham MJ: Reasons for the Termination of Interleukin-17 Inhibitor Medications in the Treatment of Plaque Psoriasis: A Real-World Retrospective Study. J Cutan Med Surg 2023, 27(1):67-69.
  42. Gulliver W, Gooderham MJ, Zhu B, Jossart C, Montmayeur S, Burge R, Reed C: Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program. Dermatol Ther (Heidelb) 2023, 13(1):235-244.
  43. Capozza K, Funk M, Hering M, Lang J, Merhand S, Manion R, Orevillo K, Picozza M, Proctor A, Schwennesen T et al: Patients’ and Caregivers’ Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries. J Allergy Clin Immunol Pract 2023, 11(1):264-273.e261.
  44. Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR et al: Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. The Journal of allergy and clinical immunology 2023, 151(1):172-181.
  45. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R, Acosta-Madiedo AS, Wen A, Moreno-López S, MacDonald M et al: Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The Journal of allergy and clinical immunology 2023, 151(1):147-158.
  46. Abduelmula A, Mufti A, Mistry J, Sachdeva M, Beecker J, Prajapati VH, Yeung J: Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review. J Cutan Med Surg 2023, 27(1):73-75.
  47. Pavel AB, Del Duca E, Cheng J, Wu J, Ungar B, Estrada YD, Jack C, Maari C, Proulx É S, Ramirez-Valle F et al: Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases. Allergy 2023, 78(1):178-191.
  48. Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E et al: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 2023, 88(1):40-51.
  49. Blauvelt A, Kircik L, Papp KA, Simpson EL, Silverberg JI, Kim BS, Kwatra SG, Kuligowski ME, Venturanza ME, Wei S et al: Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2023, 37(1):137-146.
  50. Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E et al: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2023, 88(1):29-39.